Global health challenges can be resolved using digital technology: Dr Alain Labrique

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Elekta and IAEA partner to improve access to cancer care in underserved countries

Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden

Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension

The approval bolsters the company's Mycophenolate Mofetil portfolio

Lupin receives USFDA approval for Pirfenidone Capsules

Pirfenidone Capsules had estimated annual sales of USD 95 million in the US

European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ

KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Lupin receives approval from USFDA for Pirfenidone Tablets

This product will be manufactured at Lupin's Pithampur facility in India

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers

IBL Healthcare invests in KNISS Laboratories

KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.